Qelbree 100 mg 24HR Extended Release Oral Capsule
RxNorm 2536554
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2536554 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Qelbree 100 mg 24HR Extended Release Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SYPrescribable
Synonym (SY):
24 HR Qelbree 100 mg Extended Release Oral Capsule
(Atom ID: 12623729)
SBDPrescribable
Semantic Branded Drug (SBD):
24 HR viloxazine 100 mg Extended Release Oral Capsule [Qelbree]
(Atom ID: 12623727)
SYPrescribable
Synonym (SY):
Qelbree 100 mg 24 HR Extended Release Oral Capsule
(Atom ID: 12623736)
PSNPrescribable
Prescribable Name (PSN):
Qelbree 100 mg 24HR Extended Release Oral Capsule
(Atom ID: 12623728)
Patient Education
Viloxazine
Viloxazine is used as part of a total treatment program to increase the ability to pay attention and decrease impulsiveness and hyperactivity in children 6 to 17 years of age with attention deficit hyperactivity disorder (ADHD). Viloxazine is in a class of medications called selective norepinephrine reuptake inhibitors. It works by increasing the levels of norepinephrine, a natural substance in the brain that is needed to control behavior.
[Learn More]
* Please review the disclaimer below.